SUNRISE, Fla., Sept. 22, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) today announced it was one of the presenters at the Cell Therapy Commercialization Summit in Boston along with Genzyme, Genentech, Geron and others. Bioheart was also selected as one of only eight cell therapy companies to participate in the Cell Therapy Investor Forum.
Kristin Comella, Bioheart's Chief Scientific Officer, was invited to present the Bioheart experience as part of the Clinical Development Strategies session. Ms. Comella stated, "It was an honor to participate in the Summit with so many esteemed scientists and business leaders. The field of regenerative medicine is about to experience exponential growth, and Bioheart is perfectly positioned to be a leader in this area."
Founded in 1999, Bioheart is one of the original cell therapy companies and treated its first clinical patient for congestive heart failure in 2001. Since that time, more than 400 patients have been treated with Myoblast therapy.
Bioheart has approvals for a variety of clinical trials throughout the world, including a Phase II/III Trial in the US using muscle derived stem cells and a Phase I/II trial in Mexico using adipose derived cells.
Click here to watch a clip of Kristin Comella discuss the different types of stem cells
http://www.youtube.com/watch?v=5pg5iFf8V3I&feature=mfu_in_order&list=UL
About Bioheart, Inc.
Bioheart is focused on completing the Phase II/III MARVEL study for chronic heart failure using MyoCell. The product candidate has been in clinical trials since May of 2001 with the goal of commercial approval with the current clinical program. There are approximately 130 more patients needed to complete the randomized, double blinded, placebo controlled MARVEL trial. In part one of the MARVEL trial, the performance of MyoCell was nearly 500% above its primary end point goal of 16 meters improvement in exercise capacity testing. MyoCell treated patients improved 91.7 meters while placebo patients declined 4 meters.
MyoCell is a muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the intended purpose of improving cardiac function and quality of life in chronic heart failure patients.
For more information on Bioheart, visit www.globenewswire.com/newsroom/ctr%3Fd=227994%26l=7%26a=http%253A%252F%252Fwww.bioheartinc.com%26u=http%253A%252F%252Fus.lrd.yahoo.com%252F_ylt%253DAlOSZ9CEXfT3uibZcyJcgLWxcq9_%253B_ylu%253DX3oDMTE2cnJmdW9hBHBvcwMxBHNlYwNuZXdzYXJ0Ym9keQRzbGsDaHR0cHd3d2Jpb2hl%252FSIG%253D11fguppga%252FEXP%253D1312565712%252F%252A%252Ahttp%25253A%252Fwww.bioheartinc.com%252F">http://www.bioheartinc.com.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2011.